title: Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.
abstract: Tumor angiogenesis pathways have been identified as important therapeutic targets in non-small cell lung cancer. However, no biomarkers have been described as predictors of response to antiangiogenic therapy in these patients. In this study, plasma levels of VEGF, bFGF, E-selectin, and S-ICAM and gene expression profiles of peripheral blood mononuclear cells from non-small cell lung cancer patients treated with chemotherapy plus bevacizumab were analyzed before and after treatment. Values were correlated with clinicopathological characteristics and treatment response. Plasma factor levels were measured using commercially available ELISA kits. The TaqMan(®) human angiogenesis array was used to investigate the effect of treatment on gene expression profiles. Kyoto Encyclopedia of Genes and Genomes and Gene Ontology enrichment analysis was performed for differentially expressed genes using WEB-based GEne SeT AnaLysis Toolkit. Our results suggest a benefit for patients with increased plasma levels of VEGF, E-selectin, and S-ICAM in the course of bevacizumab treatment. Also, we identified differentially expressed genes between paired blood samples from patients before and after treatment, and significantly perturbed pathways were predicted. These changes in gene expression and levels of plasma factors could be used to assess the effectiveness of antiangiogenic therapy, in addition to standard clinical and radiological evaluations.
authors: Oncology Department, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain.
authors: Analia
authors: A
authors: Rodríguez Garzotto
authors: Translational Oncology, Instituto de Investigación Hospital 12 de Octubre (i+12), Avda de Córdoba s/n, 28041, Madrid, Spain.
authors: C Vanesa
authors: CV
authors: Díaz-García
authors: Translational Oncology, Instituto de Investigación Hospital 12 de Octubre (i+12), Avda de Córdoba s/n, 28041, Madrid, Spain.
authors: Alba
authors: A
authors: Agudo-López
authors: Translational Oncology, Instituto de Investigación Hospital 12 de Octubre (i+12), Avda de Córdoba s/n, 28041, Madrid, Spain.
authors: Elena
authors: E
authors: Prieto García
authors: Oncology Department, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain.
authors: Santiago
authors: S
authors: Ponce
authors: Oncology Department, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain.|Translational Oncology, Instituto de Investigación Hospital 12 de Octubre (i+12), Avda de Córdoba s/n, 28041, Madrid, Spain.
authors: José A
authors: JA
authors: López-Martín
authors: Oncology Department, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain.|Translational Oncology, Instituto de Investigación Hospital 12 de Octubre (i+12), Avda de Córdoba s/n, 28041, Madrid, Spain.
authors: Luis
authors: L
authors: Paz-Ares
authors: Oncology Department, Hospital Universitario 12 de Octubre, Avda de Córdoba s/n, 28041, Madrid, Spain.
authors: Lara
authors: L
authors: Iglesias
authors: Translational Oncology, Instituto de Investigación Hospital 12 de Octubre (i+12), Avda de Córdoba s/n, 28041, Madrid, Spain. agullo@h12o.es.
authors: M Teresa
authors: http://orcid.org/0000-0002-7617-6681
authors: MT
authors: Agulló-Ortuño
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D015815:Cell Adhesion Molecules / Q000097:blood; D019040:E-Selectin / Q000097:blood; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008175:Lung Neoplasms / Q000097:blood* / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D059467:Transcriptome; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor; D015815:Cell Adhesion Molecules; D019040:E-Selectin; C546936:SELE protein, human; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; D000068258:Bevacizumab
keywords: Angiogenesis; Non-small cell lung cancer; Predictive biomarkers